These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 26309036)

  • 1. Investigations into the binding of jadomycin DS to human topoisomerase IIβ by WaterLOGSY NMR spectroscopy.
    Martinez-Farina CF; McCormick N; Robertson AW; Clement H; Jee A; Ampaw A; Chan NL; Syvitski RT; Jakeman DL
    Org Biomol Chem; 2015 Nov; 13(41):10324-7. PubMed ID: 26309036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JadX is a Disparate Natural Product Binding Protein.
    Robertson AW; Forget SM; Martinez-Farina CF; McCormick NE; Syvitski RT; Jakeman DL
    J Am Chem Soc; 2016 Feb; 138(7):2200-8. PubMed ID: 26814718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Jadomycins Inhibit Type II Topoisomerases and Promote DNA Damage and Apoptosis in Multidrug-Resistant Triple-Negative Breast Cancer Cells.
    Hall SR; Toulany J; Bennett LG; Martinez-Farina CF; Robertson AW; Jakeman DL; Goralski KB
    J Pharmacol Exp Ther; 2017 Nov; 363(2):196-210. PubMed ID: 28904004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation and Synthetic Diversification of Jadomycin 4-Amino-l-phenylalanine.
    Martinez-Farina CF; Robertson AW; Yin H; Monro S; McFarland SA; Syvitski RT; Jakeman DL
    J Nat Prod; 2015 Jun; 78(6):1208-14. PubMed ID: 26035093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dynamic structure of jadomycin B and the amino acid incorporation step of its biosynthesis.
    Rix U; Zheng J; Remsing Rix LL; Greenwell L; Yang K; Rohr J
    J Am Chem Soc; 2004 Apr; 126(14):4496-7. PubMed ID: 15070349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance.
    Leontiou C; Lakey JH; Lightowlers R; Turnbull RM; Austin CA
    Mol Pharmacol; 2006 Jan; 69(1):130-9. PubMed ID: 16239602
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Forget SM; McVey J; Vining LC; Jakeman DL
    Front Microbiol; 2017; 8():432. PubMed ID: 28377749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIalpha and beta--distinct mode of action of two derivatives.
    Sai Krishna AD; Panda G; Kondapi AK
    Arch Biochem Biophys; 2005 Jun; 438(2):206-16. PubMed ID: 15907782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel jadomycins: incorporation of non-natural and natural amino acids.
    Jakeman DL; Farrell S; Young W; Doucet RJ; Timmons SC
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1447-9. PubMed ID: 15713404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel and expanded jadomycins incorporating non-proteogenic amino acids.
    Jakeman DL; Graham CL; Reid TR
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5280-3. PubMed ID: 16185863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation.
    Shapiro AB; Austin CA
    Anal Biochem; 2014 Mar; 448():23-9. PubMed ID: 24309019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosynthesis, synthetic studies, and biological activities of the jadomycin alkaloids and related analogues.
    de Koning CB; Ngwira KJ; Rousseau AL
    Alkaloids Chem Biol; 2020; 84():125-199. PubMed ID: 32416952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo.
    Linka RM; Porter AC; Volkov A; Mielke C; Boege F; Christensen MO
    Nucleic Acids Res; 2007; 35(11):3810-22. PubMed ID: 17526531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of a jadomycin incorporating L-ornithine, analysis of antimicrobial activity and jadomycin reactive oxygen species (ROS) generation in MDA-MB-231 breast cancer cells.
    Forget SM; Robertson AW; Hall SR; MacLeod JM; Overy DP; Kerr RG; Goralski KB; Jakeman DL
    J Antibiot (Tokyo); 2018 Aug; 71(8):722-730. PubMed ID: 29700425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
    Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
    Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Jadomycins: A potential chemotherapy for multi-drug resistant metastatic breast cancer.
    Bonitto EP; McKeown BT; Goralski KB
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00886. PubMed ID: 34708587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereochemical integrity of oxazolone ring-containing jadomycins.
    Borissow CN; Graham CL; Syvitski RT; Reid TR; Blay J; Jakeman DL
    Chembiochem; 2007 Jul; 8(10):1198-203. PubMed ID: 17570722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, cytotoxicity and topoisomerase inhibition properties of multifarious aminoalkylated indeno[1,2-c]isoquinolin-5,11-diones.
    Ahn G; Schifano-Faux N; Goossens JF; Baldeyrou B; Couture A; Grandclaudon P; Lansiaux A; Ryckebusch A
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2259-63. PubMed ID: 21439821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of friedelan triterpenoid analogs with DNA topoisomerase IIα inhibitory activity and their molecular docking studies.
    Mandal A; Ghosh S; Bothra AK; Nanda AK; Ghosh P
    Eur J Med Chem; 2012 Aug; 54():137-43. PubMed ID: 22633831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
    Chen W; Qiu J; Shen YM
    Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.